<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases.</p><p>The deal is expected to close between late second quarter and early third quarter of 2026. </p><p>The deal includes $2 billion paid upfront and up to $200 million tied to future milestones.</p><p>The acquisition helps UCB expand its work in next-generation biologic drugs and improve treatments for conditions where the immune system attacks the body.</p><p>UCB said the financial impact will be manageable, and its 2026 outlook remains unchanged, with steady revenue and profit growth expected.</p><p>Candid's main drug, cizutamig, is an early-stage treatment designed to help the immune system target harmful cells. It is currently being tested in several Phase 1 studies for autoimmune diseases.</p><p>On Friday, UCB closed trading 0.57% higher at $33.52 on the New York Stock Exchange. </p><p>On Friday, Candel Therapeutics closed trading 4.69% higher at $6.47 on the Nasdaq. In the overnight, the stock further traded 3.40% higher at $6.69, 0.22 cents up. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

CADL

SBIO

<p>United Community Banks, Inc. (UCB) has agreed to acquire Candel Therapeutics, Inc. (CADL) for up to $2.2 billion to enhance its immunology pipeline. The deal, which includes $2 billion upfront and up to $200 million based on future milestones, is expected to close between late Q2 and early Q3 of 2026. UCB anticipates manageable financial impact and steady growth in revenue and profit. Candel's main drug, cizutamig, is in Phase 1 trials for autoimmune diseases. UCB's stock rose 0.57% to $33.52, while Candel's stock increased 4.69% to $6.47.</p>

rttnews

Candel Therapeutics

United Community Banks

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

United Community Banks, Inc.

UNITED CMNTY BKS INC 6.875% DEP SHS REP 1/1000 NON CU PF SR I

UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline